Devyser Diagnostics Salute del bilancio
Criteri Salute finanziaria verificati 6/6
Devyser Diagnostics ha un patrimonio netto totale di SEK381.0M e un debito totale di SEK200.0K, che porta il suo rapporto debito/patrimonio netto a 0.05%. Le sue attività totali e le sue passività totali sono rispettivamente SEK493.1M e SEK112.1M. L'EBIT di Devyser Diagnostics è SEK34.8M rendendo il suo rapporto di copertura degli interessi -6. Ha liquidità e investimenti a breve termine pari a SEK81.0M.
Informazioni chiave
0.052%
Rapporto debito/patrimonio netto
SEK 200.00k
Debito
| Indice di copertura degli interessi | -6x |
| Contanti | SEK 81.00m |
| Patrimonio netto | SEK 381.00m |
| Totale passività | SEK 112.10m |
| Totale attività | SEK 493.10m |
Aggiornamenti recenti sulla salute finanziaria
We Think Devyser Diagnostics (STO:DVYSR) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Companies Like Devyser Diagnostics (STO:DVYSR) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Recent updates
DVYSR: Italian Tender And New Chimerism Assay Will Support Future Upside
Analysts have reduced their price target for Devyser Diagnostics to SEK 97.58 from SEK 120.86, citing updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News for Devyser Diagnostics Devyser Diagnostics launched the One Lambda Devyser Chimerism Plus assay for chimerism analysis after allogeneic hematopoietic stem cell transplantation, focused on reducing testing errors and improving laboratory efficiency.DVYSR: Italian Tender Wins Will Support Long-Term Genetic Diagnostics Momentum
Analysts have trimmed their price target for Devyser Diagnostics to SEK120.86 from SEK156.12, citing updated assumptions for revenue growth, profit margins, discount rate and future P/E that point to a more conservative valuation framework. What's in the News Devyser Diagnostics launched One Lambda Devyser Chimerism Plus, a next generation solution for chimerism analysis following allogeneic hematopoietic stem cell transplantation.Some Devyser Diagnostics AB (publ) (STO:DVYSR) Analysts Just Made A Major Cut To Next Year's Estimates
The latest analyst coverage could presage a bad day for Devyser Diagnostics AB (publ) ( STO:DVYSR ), with the analysts...
R&D And Partner Risks Will Pressure Margins Before Long-Term Genetics Demand Emerges
Catalysts About Devyser Diagnostics Devyser Diagnostics develops and sells genetic testing kits and services for hereditary disease and transplantation applications. What are the underlying business or industry changes driving this perspective?Devyser Diagnostics' (STO:DVYSR) Earnings Are Of Questionable Quality
Devyser Diagnostics AB (publ) ( STO:DVYSR ) just reported some strong earnings, and the market reacted accordingly with...Devyser Diagnostics AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a good week for Devyser Diagnostics AB (publ) ( STO:DVYSR ) shareholders, because the company has just...We Think Devyser Diagnostics (STO:DVYSR) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Earnings Update: Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts
Devyser Diagnostics AB (publ) ( STO:DVYSR ) shareholders are probably feeling a little disappointed, since its shares...Earnings Miss: Devyser Diagnostics AB (publ) Missed EPS And Analysts Are Revising Their Forecasts
It's been a sad week for Devyser Diagnostics AB (publ) ( STO:DVYSR ), who've watched their investment drop 17% to kr108...Are Investors Undervaluing Devyser Diagnostics AB (publ) (STO:DVYSR) By 21%?
Key Insights The projected fair value for Devyser Diagnostics is kr156 based on 2 Stage Free Cash Flow to Equity...Devyser Diagnostics AB (publ) Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Shareholders of Devyser Diagnostics AB (publ) ( STO:DVYSR ) will be pleased this week, given that the stock price is up...Revenues Tell The Story For Devyser Diagnostics AB (publ) (STO:DVYSR) As Its Stock Soars 31%
Devyser Diagnostics AB (publ) ( STO:DVYSR ) shares have continued their recent momentum with a 31% gain in the last...Optimistic Investors Push Devyser Diagnostics AB (publ) (STO:DVYSR) Shares Up 27% But Growth Is Lacking
Devyser Diagnostics AB (publ) ( STO:DVYSR ) shareholders are no doubt pleased to see that the share price has bounced...Devyser Diagnostics AB (publ) (STO:DVYSR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
The analysts might have been a bit too bullish on Devyser Diagnostics AB (publ) ( STO:DVYSR ), given that the company...Companies Like Devyser Diagnostics (STO:DVYSR) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Devyser Diagnostics AB (publ) (STO:DVYSR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Last week saw the newest full-year earnings release from Devyser Diagnostics AB (publ) ( STO:DVYSR ), an important...Analysts Just Made A Substantial Upgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) Forecasts
Shareholders in Devyser Diagnostics AB (publ) ( STO:DVYSR ) may be thrilled to learn that the analysts have just...Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 27% But Many Are Still Ignoring The Company
The Devyser Diagnostics AB (publ) ( STO:DVYSR ) share price has done very well over the last month, posting an...Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported And Analysts Have Been Cutting Their Estimates
It's been a pretty great week for Devyser Diagnostics AB (publ) ( STO:DVYSR ) shareholders, with its shares surging 16...Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 28% But Many Are Still Ignoring The Company
Devyser Diagnostics AB (publ) ( STO:DVYSR ) shares have had a really impressive month, gaining 28% after a shaky period...These Analysts Just Made An Incredible Downgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) EPS Forecasts
Today is shaping up negative for Devyser Diagnostics AB (publ) ( STO:DVYSR ) shareholders, with the analysts delivering...Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( SEK206.0M ) di DVYSR superano le sue passività a breve termine ( SEK70.6M ).
Passività a lungo termine: Le attività a breve termine di DVYSR ( SEK206.0M ) superano le sue passività a lungo termine ( SEK41.5M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: DVYSR ha più liquidità del suo debito totale.
Riduzione del debito: Il rapporto debito/patrimonio netto di DVYSR si è ridotto da 1.8% a 0.05% negli ultimi 5 anni.
Copertura del debito: Il debito di DVYSR è ben coperto dal flusso di cassa operativo ( 12950% ).
Copertura degli interessi: DVYSR matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.
Bilancio
Scoprire le aziende sane
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/09 03:37 |
| Prezzo dell'azione a fine giornata | 2026/08/07 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Devyser Diagnostics AB (publ) è coperta da 4 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Erik Hultgård | Carnegie Investment Bank AB |
| Erik Hultgård | DNB Carnegie |
| Ludvig Lundgren | Nordea Markets |